First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.

[1]  R. Xu,et al.  Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  Donal B O'Connor,et al.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. , 2020, The New England journal of medicine.

[3]  S. Targan,et al.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. , 2019, The New England journal of medicine.

[4]  T. Matsui,et al.  Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study , 2019, PloS one.

[5]  Siddharth Singh,et al.  328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis , 2018 .

[6]  S. Bonovas,et al.  Systematic review with network meta‐analysis: comparative assessment of tofacitinib and biological therapies for moderate‐to‐severe ulcerative colitis , 2018, Alimentary pharmacology & therapeutics.

[7]  M. Murad,et al.  Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis , 2018, Alimentary pharmacology & therapeutics.

[8]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[9]  Siddharth Singh,et al.  Comparison of Infliximab and Adalimumab in Biologic‐Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  Siddharth Singh,et al.  Natural History of Adult Ulcerative Colitis in Population‐based Cohorts: A Systematic Review , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  B. Hutton,et al.  The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  S. Vermeire,et al.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis , 2017, The New England journal of medicine.

[13]  T. Hibi,et al.  Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study) , 2017, Journal of Gastroenterology.

[14]  C. Ainsworth,et al.  Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis , 2016, PloS one.

[15]  S. Bonovas,et al.  Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  L. Peyrin-Biroulet,et al.  Biologic agents for IBD: practical insights , 2015, Nature Reviews Gastroenterology &Hepatology.

[17]  Jing Gao,et al.  Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis , 2015, Journal of clinical gastroenterology.

[18]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[19]  J. Gisbert,et al.  Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed , 2015, Alimentary pharmacology & therapeutics.

[20]  Mohammad Hassan Murad,et al.  A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis , 2014, BMJ : British Medical Journal.

[21]  P. Munkholm,et al.  Disease Course and Surgery Rates in Inflammatory Bowel Disease: A Population-Based, 7-Year Follow-Up Study in the Era of Immunomodulating Therapy , 2014, The American Journal of Gastroenterology.

[22]  T. Hibi,et al.  Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis , 2013, Journal of Gastroenterology.

[23]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[24]  Dan Jackson,et al.  Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression‡ , 2012, Research synthesis methods.

[25]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[26]  Joseph C Cappelleri,et al.  Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  Georgia Salanti,et al.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.

[28]  D. Hommes,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[29]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[30]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[31]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[32]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[33]  P. Rutgeerts,et al.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[34]  P. Rutgeerts,et al.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[35]  U. Gasthuisberg.  Infliximab for induction and maintenance therapy for ulcerative colitis , 2006 .